167 filings
Page 3 of 9
UPLOAD
djlhg1vfdo4po35npful
30 Jun 22
Letter from SEC
12:00am
8-K
fpxjxcvwr
23 Jun 22
Entry into a Material Definitive Agreement
4:25pm
8-K
guea8
3 Jun 22
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
8:10am
8-K
w2vitmgvtk1
19 May 22
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
8:10am
8-K
rr6o nhh8x
30 Mar 22
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
7:28am
8-K
fqm41iz6si2nad twg
3 Feb 22
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
8:16am
8-K
2d27qn wrqi9
31 Jan 22
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
4:15pm
8-K
znmix xziqe
10 Jan 22
Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones
8:29am
8-K
7eku 7s5zsl
2 Dec 21
Replimune Appoints Christy Oliger to its Board of Directors
9:15am
8-K
qoph ncjg1
4 Nov 21
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
8:13am
8-K
xvbjjl
9 Sep 21
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
y5vv8 tjiuxycmjom
25 Aug 21
Departure of Directors or Certain Officers
4:15pm
CT ORDER
q2utvkhhs sb0
18 Aug 21
Confidential treatment order
12:00am
8-K
gqz7ughe015b dgja
6 Aug 21
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
8:00am
DEFA14A
8yg snnm5wf
22 Jul 21
Additional proxy soliciting materials
4:01pm